- Home
- EQBK vs LIMN Comparison
EQBK vs LIMN Comparison
Compare EQBK & LIMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQBK
- LIMN
- Stock Information
- Founded
- EQBK 2002
- LIMN 2018
- Country
- EQBK United States
- LIMN United States
- Employees
- EQBK N/A
- LIMN N/A
- Industry
- EQBK Major Banks
- LIMN
- Sector
- EQBK Finance
- LIMN
- Exchange
- EQBK Nasdaq
- LIMN NYSE
- Market Cap
- EQBK 696.9M
- LIMN 623.8M
- IPO Year
- EQBK 2015
- LIMN N/A
- Fundamental
- Price
- EQBK $36.51
- LIMN $5.93
- Analyst Decision
- EQBK Buy
- LIMN
- Analyst Count
- EQBK 6
- LIMN 0
- Target Price
- EQBK $45.60
- LIMN N/A
- AVG Volume (30 Days)
- EQBK 102.9K
- LIMN 987.0K
- Earning Date
- EQBK 07-14-2025
- LIMN 01-01-0001
- Dividend Yield
- EQBK 1.60%
- LIMN N/A
- EPS Growth
- EQBK 541.52
- LIMN N/A
- EPS
- EQBK 4.01
- LIMN N/A
- Revenue
- EQBK $227,863,000.00
- LIMN N/A
- Revenue This Year
- EQBK $20.94
- LIMN N/A
- Revenue Next Year
- EQBK $10.08
- LIMN N/A
- P/E Ratio
- EQBK $9.37
- LIMN N/A
- Revenue Growth
- EQBK 49.19
- LIMN N/A
- 52 Week Low
- EQBK $32.95
- LIMN $4.40
- 52 Week High
- EQBK $50.85
- LIMN $33.66
- Technical
- Relative Strength Index (RSI)
- EQBK 26.42
- LIMN N/A
- Support Level
- EQBK $37.85
- LIMN N/A
- Resistance Level
- EQBK $38.79
- LIMN N/A
- Average True Range (ATR)
- EQBK 0.91
- LIMN 0.00
- MACD
- EQBK -0.47
- LIMN 0.00
- Stochastic Oscillator
- EQBK 6.83
- LIMN 0.00
About EQBK Equity Bancshares Inc.
Equity Bancshares Inc is a bank holding company. It provides a broad range of financial services to businesses and business owners as well as individuals through network of nearly 71 branches located in Arkansas, Kansas, Missouri and Oklahoma. The majority of the Company's revenues come from interest income on financial instruments, including loans, leases, securities and derivatives. The company also earns revenue from Non-interest income which includes Service charges and fees, Debit card income, Investment Referral Income, Trust Income and Insurance Sales Commissions.
About LIMN LIMINATUS PHARMA INC
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C.